Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.blre.2020.100775 http://scihub22266oqcxt.onion/10.1016/j.blre.2020.100775 33187811!7833659!33187811     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33187811&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Blood+Rev 2021 ; 47 (?): 100775 Nephropedia Template TP {{tp|p=33187811|t=2021. When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities |pdf=|usr=}}{{33187811}} gab.com Text When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities JO: Blood Rev http://www.kidney.de/pget.php?&tw=1&pmid=33187811 #FOAvip Scientific data is limited on the risks, adverse outcomes and racial disparities for COVID-19 illness in individuals with hematologic malignancies in the United States. To fill this void, we screened and analyzed a nation-wide database of patient electronic health records (EHRs) of 73 million patients in the US (up to September 1st) for COVID-19 and eight major types of hematologic malignancies. Patients with hematologic malignancies had increased odds of COVID-19 infection compared with patients without hematologic malignancies for both all-time diagnosis (malignancy diagnosed in the past year or prior) (adjusted Odds ratio or AOR: 2.27 [2.17-2.36], p < 0.001) and recent diagnosis (malignancy diagnosed in the past year) (AOR:11.91 [11.31-12.53], p < 0.001), with strongest effect for recently diagnosed acute lymphoid leukemia (AOR: 31.03 [25.87-37.27], p < 0.001), essential thrombocythemia (AOR: 20.65 [19.10-22.32], p < 0.001), acute myeloid leukemia (AOR: 18.94 [15.79-22.73], p < 0.001), multiple myeloma (AOR: 14.21 [12.72-15.89], p < 0.001). Among patients with hematologic malignancies, African Americans had higher odds of COVID-19 infection than Caucasians with largest racial disparity for multiple myeloma (AOR: 4.23 [3.21-5.56], p < 0.001). Patients with recently diagnosed hematologic malignancies had worse outcomes (hospitalization: 51.9%, death: 14.8%) than COVID-19 patients without hematologic malignancies (hospitalization: 23.5%, death: 5.1%) (p < 0.001) and hematologic malignancy patients without COVID-19 (hospitalization: 15.0%, death: 4.1%) (p < 0.001). Twit Text FOAVip When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities ????Blood Rev http://www.kidney.de/pget.php?&tw=1&pmid=33187811 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33187811 #FOAvip English Wikipedia <ref>{{Cite pmid|33187811}}</ref> When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities #MMPMID33187811 Wang Q; Berger NA; Xu R Blood Rev 2021[May]; 47 (?): 100775 PMID33187811show ga Scientific data is limited on the risks, adverse outcomes and racial disparities for COVID-19 illness in individuals with hematologic malignancies in the United States. To fill this void, we screened and analyzed a nation-wide database of patient electronic health records (EHRs) of 73 million patients in the US (up to September 1st) for COVID-19 and eight major types of hematologic malignancies. Patients with hematologic malignancies had increased odds of COVID-19 infection compared with patients without hematologic malignancies for both all-time diagnosis (malignancy diagnosed in the past year or prior) (adjusted Odds ratio or AOR: 2.27 [2.17-2.36], p < 0.001) and recent diagnosis (malignancy diagnosed in the past year) (AOR:11.91 [11.31-12.53], p < 0.001), with strongest effect for recently diagnosed acute lymphoid leukemia (AOR: 31.03 [25.87-37.27], p < 0.001), essential thrombocythemia (AOR: 20.65 [19.10-22.32], p < 0.001), acute myeloid leukemia (AOR: 18.94 [15.79-22.73], p < 0.001), multiple myeloma (AOR: 14.21 [12.72-15.89], p < 0.001). Among patients with hematologic malignancies, African Americans had higher odds of COVID-19 infection than Caucasians with largest racial disparity for multiple myeloma (AOR: 4.23 [3.21-5.56], p < 0.001). Patients with recently diagnosed hematologic malignancies had worse outcomes (hospitalization: 51.9%, death: 14.8%) than COVID-19 patients without hematologic malignancies (hospitalization: 23.5%, death: 5.1%) (p < 0.001) and hematologic malignancy patients without COVID-19 (hospitalization: 15.0%, death: 4.1%) (p < 0.001). |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |COVID-19/*epidemiology[MESH] |Female[MESH] |Health Status Disparities[MESH] |Hematologic Neoplasms/*complications/epidemiology[MESH] |Hospitalization[MESH] |Humans[MESH] |Leukemia, Myeloid, Acute/complications/epidemiology[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Myeloma/complications/epidemiology[MESH] |Odds Ratio[MESH] |Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications/epidemiology[MESH] |Risk Factors[MESH] |SARS-CoV-2/isolation & purification[MESH] |United States/epidemiology[MESH]When hematologic malignancies meet COVID-19 in the United States: Infe(epmc).pdf DeepDyve Pubget Overpricing